Public U.S. telehealth platform, Hims & Hers Health, announced on February 19, 2026 that it has entered into a definitive agreement to acquire Eucalyptus, an Australia-based international digital health company, in a transaction valued at up to $1.15Bn. The deal represents cross-border consolidations in the telehealth sector and marks a step in Hims & Hers’ strategy to build a leading global consumer health platform.

Acquisition Overview

Under the terms of the agreement, approximately $240MM will be paid in cash upon closing, with the remaining consideration structured as guaranteed deferred payments over an 18-month post-close period and additional earn-out payments tied to financial performance targets through early 2029. Hims & Hers retains the option to settle the majority of deferred and earn-out payments in either cash or stock, affording meaningful balance sheet flexibility.

The acquisition is subject to customary regulatory approvals and closing conditions and is expected to close in mid-2026.

Strategic Overview

The acquisition provides Hims & Hers with immediate entry into the Australian market and a pathway into Japan, while deepening its existing footprint in the United Kingdom, Germany and Canada. Eucalyptus operates a portfolio of consumer-facing digital health brands — including weight management platform Juniper, men’s telehealth brand Pilot and reproductive health company Kin — and serves more than 775,000 customers across its markets.

The transaction also complements a series of recent international acquisitions by Hims & Hers, including European digital health platform ZAVA, which expanded Hims & Hers’ presence in Germany, France, Ireland and the UK, and Canadian digital health platform Livewell. Together, these acquisitions are expected to create a diversified international platform spanning a broad range of service models, from online pharmacy fulfillment to concierge-style personalized care.

Market Context

The transaction arrives amid growing investor focus on the global GLP-1 opportunity. The GLP-1 therapeutics market, estimated at approximately $15Bn in 2024, is projected by industry observers to reach $150Bn by 2035, with international market penetration currently below three percent. Digital health platforms with established distribution infrastructure and regulatory expertise are increasingly well-positioned to capitalize on this expansion as branded and generic weight management treatments scale globally.

The deal also comes at a sensitive moment for Hims & Hers domestically. The company recently withdrew a newly launched compounded semaglutide pill following regulatory pressure from the U.S. Food and Drug Administration and a lawsuit from Novo Nordisk, the manufacturer of branded weight-loss drug Wegovy. The acquisition of Eucalyptus may be viewed in part as a strategic effort to diversify the Hims & Hers’ revenue base and reduce its dependence on compounding pharmacy activity in the U.S.

Takeaway

The acquisition of Eucalyptus positions Hims & Hers in a favorable position in the rapidly consolidating global telehealth landscape. By combining established international infrastructure with a proven domestic playbook, Hims & Hers is making a calculated bet that the demand for personalized, digitally delivered healthcare is not a U.S.-specific phenomenon but rather a generational shift in how consumers around the world engage with their health. Whether the combined platform can execute across multiple regulatory environments is likely to be the defining question for investors in the quarters ahead.

About DelMorgan & Co. (www.delmorganco.com)

With over $300 billion of successful transactions in over 80 countries, DelMorgan‘s Investment Banking professionals have worked on some of the most challenging, most rewarding and highest profile transactions in the U.S. and around the globe. DelMorgan specializes in capital raising and M&A advisor services for companies across all industries and is recognized as one of the leading investment banking practices in California and globally.